Clinuvel Pharmaceuticals Limited (ASX:CUV)
Australia · Delayed Price · Currency is AUD 8.47
-0.71 (-7.73%)
Aug 28, 2026, 4:10 PM AEST
Clinuvel Pharmaceuticals Cash Flow Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Net Income | 33.92 | 36.17 | 35.64 | 30.6 | 20.88 |
Depreciation & Amortization | 0.99 | 1.15 | 1.09 | 0.74 | 0.72 |
Loss (Gain) From Sale of Assets | 0.06 | - | - | - | 0.03 |
Stock-Based Compensation | 2.34 | 2 | 6.11 | 8.99 | 6.12 |
Provision & Write-off of Bad Debts | -0.15 | - | - | - | - |
Other Operating Activities | 3.03 | -0.42 | 0.67 | -0.21 | 0.17 |
Change in Accounts Receivable | 4.16 | -1.22 | -4.02 | -6.01 | -0.11 |
Change in Inventory | 1.94 | 1.81 | -1.11 | -7.69 | 1.35 |
Change in Accounts Payable | -0.7 | 2.84 | -0.65 | 4.51 | -1.56 |
Change in Income Taxes | -7.83 | -1.3 | -0.24 | 8.81 | 7.18 |
Change in Other Net Operating Assets | 0.96 | -0.87 | 0.07 | -1.41 | -0.97 |
Operating Cash Flow | 36.91 | 41.1 | 37.05 | 36.91 | 39.87 |
Operating Cash Flow Growth | -10.18% | 10.91% | 0.38% | -7.42% | 107.00% |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Capital Expenditures | -1.6 | -0.3 | -5.58 | -1.03 | -0.43 |
Investment in Securities | -37.52 | -47.42 | -23.46 | -30.82 | - |
Investing Cash Flow | -39.12 | -47.72 | -29.03 | -31.85 | -0.43 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Long-Term Debt Repaid | -0.24 | -0.18 | -0.35 | -0.26 | -0.27 |
Net Debt Issued (Repaid) | -0.24 | -0.18 | -0.35 | -0.26 | -0.27 |
Issuance of Common Stock | 0.56 | 0.19 | 4.16 | - | - |
Repurchase of Common Stock | -0.56 | -0.44 | -4.91 | - | - |
Common Dividends Paid | -2.51 | -2.5 | -2.47 | -1.98 | -1.24 |
Other Financing Activities | -0.01 | - | - | - | - |
Financing Cash Flow | -2.75 | -2.94 | -3.57 | -2.24 | -1.5 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Foreign Exchange Rate Adjustments | -1.67 | 2.38 | -1.14 | 1.66 | 0.88 |
Net Cash Flow | -6.63 | -7.18 | 3.31 | 4.48 | 38.82 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | 35.31 | 40.8 | 31.48 | 35.88 | 39.44 |
Free Cash Flow Growth | -13.46% | 29.61% | -12.28% | -9.01% | 114.25% |
Free Cash Flow Margin | 37.55% | 42.94% | 35.70% | 45.82% | 60.01% |
Free Cash Flow Per Share | 0.70 | 0.81 | 0.62 | 0.69 | 0.76 |
Levered Free Cash Flow | 25.39 | 29.91 | 23.45 | 32.33 | 33.25 |
Unlevered Free Cash Flow | 25.39 | 29.91 | 26.23 | 34.33 | 34.67 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash Income Tax Paid | 23.36 | 15.73 | 15.65 | 7.74 | - |
Change in Working Capital | -3.26 | 2.2 | -6.44 | -3.22 | 11.96 |